Author:
Li Ran,Xu Chang-qiong,Shen Jian-xin,Ren Qiu-yun,Chen Di-ling,Lin Mian-jie,Huang Rong-ni,Li Chun-hui,Zhong Ru-ting,Luo Zhi-hua,Ji Xiao-yu,Wu Jie
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference32 articles.
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. Gao J, Wang Z, Liu H, Wang L, Huang G. Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation. Drug Discov Ther. 2015;9:205–12.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
4. Yu ZY, Xie GF, Zhou GT, Cheng Y, Zhang GT, Yao GM, et al. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Cancer Lett. 2015;367:58–68.
5. National Pharmacopoeia Committee. Pharmacopoeia of the People’s Republic of China (part I). Beijing: China Medical Science and Technology Press; 2015. p. 229–30.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献